Success Metrics

Clinical Success Rate
84.2%

Based on 32 completed trials

Completion Rate
84%(32/38)
Active Trials
8(14%)
Results Posted
75%(24 trials)
Terminated
6(11%)

Phase Distribution

Ph not_applicable
1
2%
Ph phase_1
3
5%
Ph phase_2
9
16%
Ph phase_3
13
23%
Ph early_phase_1
3
5%
Ph phase_4
20
35%

Phase Distribution

6

Early Stage

9

Mid Stage

33

Late Stage

Phase Distribution49 total trials
Early Phase 1First-in-human
3(6.1%)
Phase 1Safety & dosage
3(6.1%)
Phase 2Efficacy & side effects
9(18.4%)
Phase 3Large-scale testing
13(26.5%)
Phase 4Post-market surveillance
20(40.8%)
N/ANon-phased studies
1(2.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.0%

32 of 41 finished

Non-Completion Rate

22.0%

9 ended early

Currently Active

8

trials recruiting

Total Trials

57

all time

Status Distribution
Active(12)
Completed(32)
Terminated(9)
Other(4)

Detailed Status

Completed32
Terminated6
Recruiting5
unknown4
Active, not recruiting3
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
57
Active
8
Success Rate
84.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (6.1%)
Phase 13 (6.1%)
Phase 29 (18.4%)
Phase 313 (26.5%)
Phase 420 (40.8%)
N/A1 (2.0%)

Trials by Status

terminated611%
enrolling_by_invitation24%
not_yet_recruiting24%
recruiting59%
completed3256%
unknown47%
active_not_recruiting35%
withdrawn35%

Recent Activity

Clinical Trials (57)

Showing 20 of 57 trialsScroll for more
NCT04926818Phase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active Not Recruiting
NCT06408259Phase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Recruiting
NCT07483632Phase 3

A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Not Yet Recruiting
NCT04480853Phase 4

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Recruiting
NCT07220252Phase 2

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

Not Yet Recruiting
NCT05123703Phase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Active Not Recruiting
NCT01892722Phase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Active Not Recruiting
NCT05688436

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting
NCT05307731Phase 4

Fingolimod for Type 2 Diabetes Mellitus

Recruiting
NCT05285878Phase 2

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Enrolling By Invitation
NCT04088630Early Phase 1

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

Completed
NCT01285479

The Gilenya Pregnancy Registry

Completed
NCT06705608

Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed
NCT05423769

Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Completed
NCT06087965Phase 1

Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage

Unknown
NCT03943498Early Phase 1

Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

Completed
NCT03941743Phase 1

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

Completed
NCT04675762Phase 2

Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke

Recruiting
NCT04676204

Relationship Between Oral DMT Burden and Adherence in MS

Enrolling By Invitation
NCT04629872Phase 2

Fingolimod in Endovascular Treatment of Ischemic Stroke

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
57